文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

携带OXA-48样碳青霉烯酶基因肠杆菌目细菌的全球流行病学与抗菌药物耐药性:2018-2021年ATLAS项目结果启示

Global epidemiology and antimicrobial resistance of Enterobacterales harbouring genes encoding OXA-48-like carbapenemases: insights from the results of the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme 2018-2021.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

基于2018-2021年ATLAS监测项目,分析携带blaOXA-48样基因肠杆菌目细菌的全球分布与耐药性。72 244株中1934株携带该基因,以克雷伯菌属为主(86.9%),仅头孢他啶/阿维巴坦和替加环素敏感率较好,基因型与碳青霉烯耐药表型存在差异,亚洲、中东和东欧携带率最高,肺炎克雷伯菌中blaOXA-232比例从2018年23.9%升至2021年56.0%。

要点

  • 72 244株肠杆菌目中1934株携带blaOXA-48样基因,克雷伯菌属占86.9%。
  • 仅头孢他啶/阿维巴坦和替加环素敏感率较好,多重耐药率高。
  • 16.8%(233/1384)携带blaOXA-48样基因菌株对美罗培南敏感,基因型与表型不一致。

核心结论

  • 携带blaOXA-48样基因的肠杆菌目细菌广泛存在且日益增多,需加强监测、改进诊断方法并实施针对性抗菌药物管理。

研究设计与样本

  • 基于2018-2021年抗微生物药物测试领导与监测(ATLAS)项目收集肠杆菌目分离株,进行抗菌药物敏感性试验和β-内酰胺酶基因检测及统计分析。

主要发现

  • 72 244株肠杆菌目中1934株携带blaOXA-48样基因,以克雷伯菌属为主(86.9%)。
  • 多重耐药率高,仅头孢他啶/阿维巴坦和替加环素显示良好敏感性。
  • 16.8%(233/1384)携带blaOXA-48样基因菌株对美罗培南敏感;大肠埃希菌中37.4%(64/95)对美罗培南敏感,肺炎克雷伯菌25.2%(160/1184),阴沟肠杆菌复合群0%(0/36),P<0.05。
  • blaOXA-48样基因携带率最高的地区为亚洲、中东和东欧。
  • 肺炎克雷伯菌中携带blaOXA-232的比例从2018年23.9%升至2021年56.0%;blaOXA-48比例在2018-2021年间下降。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The recent emergence of carbapenem-resistant Enterobacterales poses a major and escalating threat to global public health. This study aimed to analyse the global distribution and antimicrobial resistance of Enterobacterales harbouring variant OXA-48-like carbapenemase-related genes. METHODS: Enterobacterales isolates were collected from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme during 2018-2021. Comprehensive antimicrobial susceptibility testing and β-lactamase gene detection were also conducted, along with statistical analysis of the collected data. RESULTS: Among the 72 244 isolates, 1934 Enterobacterales isolates were identified to harbour blaOXA-48-like genes, predominantly Klebsiella spp. (86.9%). High rates of multidrug resistance were observed, with only ceftazidime/avibactam and tigecycline showing favourable susceptibility. A discrepancy between the genotype and phenotype of carbapenem resistance was evident: 16.8% (233 out of 1384) of the Enterobacterales isolates with blaOXA-48-like genes exhibited susceptibility to meropenem. Specifically, 37.4% (64/95) of Escherichia coli strains with blaOXA-48-like genes displayed meropenem susceptibility, while the corresponding percentages for Klebsiella pneumoniae and Enterobacter cloacae complex were 25.2% (160/1184) and 0% (0/36), respectively (P < 0.05). Geographical analysis revealed that the highest prevalence of blaOXA-48-like genes occurred in Asia, the Middle East and Eastern Europe. The proportion of K. pneumoniae isolates harbouring blaOXA-232 increased from 23.9% in 2018 to 56.0% in 2021. By contrast, the proportion of blaOXA-48 decreased among K. pneumoniae isolates during 2018-2021. CONCLUSIONS: This study underscores the widespread and increasing prevalence of blaOXA-48-like genes in Enterobacterales and emphasizes the need for enhanced surveillance, improved diagnostic methods and tailored antibiotic stewardship to combat the spread of these resistant pathogens.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lee YL, Wang WY, Ko WC, et al. Global epidemiology and antimicrobial resistance of Enterobacterales harbouring genes encoding OXA-48-like carbapenemases: insights from the results of the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme 2018-2021. J Antimicrob Chemother. 2024. PMID: 38758189. doi:10.1093/jac/dkae140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。